Ovitrelle

ApprovedSmall molecule

Merck & Co.

Ovitrelle is one of 47 small molecule programs targeting Ovarian Reserve. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian ReserveActive, not recruiting

Breast CancerActive, not recruiting

Ovarian ReserveApproved

Active, not recruiting

Breast CancerApproved

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ovitrelle

Merck & Co.

Approved

1 2

Tykerb

GSK

Preclinical

80 3

Tecentriq

Roche

Preclinical

36 4

Prolia

Amgen

Preclinical

14 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Paracetamol

GSK

Preclinical

1 8

Zoladex

Luye Pharma Group Ltd.

Preclinical

8 9

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 10

Motexafin Gadolinium

PPharmacyclics LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Frozen Embryo Transfer

NCT06896617

Clinical

Trials by Indication[1]

Ovarian Stimulation2 trials

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

Withdrawn· Ferring logo

Ferring·Phase 2·NCT05571111

Comparison of Triggers in Double Ovarian Stimulation (DuoStim).

Unknown status·IInstituto Bernabeu·Phase 4·NCT05321511·165 enrolled

Breast Cancer1 trial

Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers

Completed·UUniversity Hospital, Ghent·Phase 4·NCT03495609·33 enrolled

Treatment1 trial

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Unknown status·HHadassah Medical Organization·N/A·NCT01205009·100 enrolled

Ovarian Reserve1 trial

hCG Priming in Women With Low Ovarian Reserve

Completed·RRigshospitalet, Denmark·Phase 4·NCT04643925·20 enrolled

ESS1 trial

EXpression PRofile Endometrium Samples Study

Terminated· Merck & Co. logo

Merck & Co.·Phase 4·NCT01210144·27 enrolled

2 more indications

Frozen Embryo Transfer1 trial

Impact of the Presence of the Corpus Luteum on Pregnancies Obtained Through Frozen Embryo Transfer(FET)

Recruiting·FFundacion Clinic per a la Recerca Biomédica·Phase 4·NCT06896617·334 enrolled

Oocyte1 trial

Follicle Size and Oocyte Development

Completed·SSheba Medical Center·N/A·NCT03660813·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ovitrelle. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ovitrelle compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ovitrelle. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

Ovitrelle

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Ovarian Stimulation2 trials

Breast Cancer1 trial

Treatment1 trial

Ovarian Reserve1 trial

ESS1 trial

Frozen Embryo Transfer1 trial

Oocyte1 trial

References

Drug Info

Quick Facts

Related News